Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic
and lymphoid tissues was last updated in 2008. Since then, there have been numerous …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …

Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has
advanced to a stage where many patients achieve very low or undetectable levels of …

The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

Background: Tyrosine kinase inhibitors (TKIs) have increased survival dramatically for
patients with chronic myeloid leukemia (CML), but continuous administration of these drugs …

Chronic myeloid leukemia (CML) accounts for approximately 15% of adult leukemias. Forty
percent of patients with CML are asymptomatic, in whom the disease is detected solely …

Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests
standardized to the International Scale (IS) is key to proper disease management, especially …

Tyrosine kinase inhibitors (TKIs) targeting BCR/ABL such as imatinib, nilotinib, dasatinib,
bosutinib and ponatinib have revolutionised the management of patients with chronic …

Relapse is a major cause of treatment failure in Philadelphia-chromosome-positive acute
lymphoblastic leukemia (Ph+ ALL) undergoing allogeneic hematopoietic cell transplantation …

Purpose: Sequential treatment with targeted therapies can result in complex combinations of
resistance mutations in drug targets. This mutational complexity has spurred the …